Tweet
BMC. Association Between Statin Therapy and Outcomes in Critically Ill Patients: a Nested Cohort Study
[Source: BMC, Clinical Pharmacology, full text: (LINK). Abstract, edited.]
Association Between Statin Therapy and Outcomes in Critically Ill Patients: a Nested Cohort Study
Shmeylan A. Al Harbi, Hani M. Tamim and Yaseen M. Arab
BMC Clinical Pharmacology 2011, 11:12doi:10.1186/1472-6904-11-12
Published: 6 August 2011
Abstract (provisional)
Background
The effect of statin therapy on mortality in critically ill patients is controversial, with some studies suggesting a benefit and others suggesting no benefit or even potential harm. The objective of this study was to evaluate the association between statin therapy during intensive care unit (ICU) admission and all-cause mortality in critically ill patients.
Methods
This was a nested cohort study within two randomised controlled trials conducted in a tertiary care ICU. All 763 patients who participated in the two trials were included in this study. Of these, 107 patients (14%) received statins during their ICU stay. The primary endpoint was all-cause ICU and hospital mortality. Secondary endpoints included the development of sepsis and severe sepsis during the ICU stay, the ICU length of stay, the hospital length of stay, and the duration of mechanical ventilation. Multivariate logistic regression was used to adjust for clinically and statistically relevant variables.
Results
Statin therapy was associated with a reduction in hospital mortality (adjusted odds ratio [aOR]=0.60, 95% confidence interval [CI] 0.36-0.99). Statin therapy was associated with lower hospital mortality in the following groups: patients >58 years of age (aOR=0.58, 95% CI 0.35-0.97), those with an acute physiology and chronic health evaluation (APACHE II) score >22 (aOR=0.54, 95% CI 0.31-0.96), diabetic patients (aOR=0.52, 95% CI 0.30-0.90), patients on vasopressor therapy (aOR=0.53, 95% CI 0.29-0.97), those admitted with severe sepsis (aOR=0.22, 95% CI 0.07-0.66), patients with creatinine [less than or equal to]100 umol/L (aOR=0.14, 95% CI 0.04-0.51), and patients with GCS [less than or equal to]9 (aOR=0.34, 95% CI 0.17-0.71). When stratified by statin dose, the mortality reduction was mainly observed with statin equipotent doses [greater than or equal to]40 mg of simvastatin (aOR=0.53, 95% CI 0.28-1.00). Mortality reduction was observed with simvastatin (aOR=0.37, 95% CI 0.17-0.81) but not with atorvastatin (aOR=0.80, 95% CI 0.84-1.46). Statin therapy was not associated with a difference in any of the secondary outcomes.
Conclusion
Statin therapy during ICU stay was associated with a reduction in all-cause hospital mortality. This association was especially noted in high-risk subgroups. This potential benefit needs to be validated in a randomised, controlled trial.
-
-------
Association Between Statin Therapy and Outcomes in Critically Ill Patients: a Nested Cohort Study
Shmeylan A. Al Harbi, Hani M. Tamim and Yaseen M. Arab
BMC Clinical Pharmacology 2011, 11:12doi:10.1186/1472-6904-11-12
Published: 6 August 2011
Abstract (provisional)
Background
The effect of statin therapy on mortality in critically ill patients is controversial, with some studies suggesting a benefit and others suggesting no benefit or even potential harm. The objective of this study was to evaluate the association between statin therapy during intensive care unit (ICU) admission and all-cause mortality in critically ill patients.
Methods
This was a nested cohort study within two randomised controlled trials conducted in a tertiary care ICU. All 763 patients who participated in the two trials were included in this study. Of these, 107 patients (14%) received statins during their ICU stay. The primary endpoint was all-cause ICU and hospital mortality. Secondary endpoints included the development of sepsis and severe sepsis during the ICU stay, the ICU length of stay, the hospital length of stay, and the duration of mechanical ventilation. Multivariate logistic regression was used to adjust for clinically and statistically relevant variables.
Results
Statin therapy was associated with a reduction in hospital mortality (adjusted odds ratio [aOR]=0.60, 95% confidence interval [CI] 0.36-0.99). Statin therapy was associated with lower hospital mortality in the following groups: patients >58 years of age (aOR=0.58, 95% CI 0.35-0.97), those with an acute physiology and chronic health evaluation (APACHE II) score >22 (aOR=0.54, 95% CI 0.31-0.96), diabetic patients (aOR=0.52, 95% CI 0.30-0.90), patients on vasopressor therapy (aOR=0.53, 95% CI 0.29-0.97), those admitted with severe sepsis (aOR=0.22, 95% CI 0.07-0.66), patients with creatinine [less than or equal to]100 umol/L (aOR=0.14, 95% CI 0.04-0.51), and patients with GCS [less than or equal to]9 (aOR=0.34, 95% CI 0.17-0.71). When stratified by statin dose, the mortality reduction was mainly observed with statin equipotent doses [greater than or equal to]40 mg of simvastatin (aOR=0.53, 95% CI 0.28-1.00). Mortality reduction was observed with simvastatin (aOR=0.37, 95% CI 0.17-0.81) but not with atorvastatin (aOR=0.80, 95% CI 0.84-1.46). Statin therapy was not associated with a difference in any of the secondary outcomes.
Conclusion
Statin therapy during ICU stay was associated with a reduction in all-cause hospital mortality. This association was especially noted in high-risk subgroups. This potential benefit needs to be validated in a randomised, controlled trial.
-
-------